Prothena Announces Leadership Team Updates
September 27 2024 - 4:05PM
Business Wire
- Chad J. Swanson, Ph.D., appointed Chief Development Officer and
will lead clinical development and medical functions
- Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an
opportunity at a large pharmaceutical company to lead a global
product development division
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company with a robust pipeline of investigational
therapeutics built on protein dysregulation expertise, today
announced that Chad Swanson, Ph.D., has been appointed Chief
Development Officer and will assume leadership of clinical
development and medical functions. Chad will join Prothena’s
executive leadership team and will report to Gene Kinney, Ph.D.,
President and Chief Executive Officer. Hideki Garren, M.D., Ph.D.,
will pursue an opportunity at a large pharmaceutical company to
lead a global product development division. Prothena will initiate
a search for a world-class healthcare leader as our next Chief
Medical Officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240927197303/en/
Chad Swanson, Ph.D., Chief Development
Officer, Prothena (Photo: Business Wire)
“We are excited to work closely with Chad in this key leadership
role, leveraging his deep clinical and research experience in
neuroscience that will enhance our ability to advance Prothena’s
broad pipeline,” said Dr. Kinney. “On behalf of our board and all
Prothenians, I would like to thank Hideki for his leadership and
the strong team and culture he helped build over the past three and
half years, as well as his forward thinking and succession planning
leading to a seamless transition for Chad to continue to lead our
robust R&D pipeline. During his tenure, Hideki helped to create
a robust clinical foundation and set Prothena on a path for future
success.”
“I am extremely proud of my time at Prothena, building and
strengthening our clinical and medical operations in support of our
many potential best-in-class therapeutics. Having recruited and
worked with Chad over the past two years, I have full confidence in
our succession plan and his ability to lead Prothena as Chief
Development Officer,” said Dr. Garren. “I believe the upcoming
meaningful clinical readouts, across multiple Prothena programs
during the next nine months and beyond, have the potential to be
transformational for millions of patients and their families across
a wide range of unmet medical needs. I have enjoyed my time and
benefited from working alongside Prothenians who have contributed
to an industry leading R&D pipeline. Prothena’s scientific
expertise in protein dysregulation is unmatched in the
industry.”
Dr. Swanson is a neuropharmacologist with over 20 years industry
experience and joined Prothena as Senior Vice President and Head of
Clinical Development in January 2023 from Eisai, Inc. where he was
the Executive Director of Clinical Research in the Alzheimer’s
Disease Brain Health group. In that role, he served as the
International Project Team Leader, responsible for all aspects of
the lecanemab program. During his 11-year tenure at Eisai, Dr.
Swanson delivered a highly innovative Phase 2 dose finding study
that established proof of concept for lecanemab in treating early
Alzheimer’s disease. Based on those Phase 2 results, he led
regulatory submission activities that resulted in the accelerated
approval of LEQEMBI™ in January 2023.
“I am excited for this great opportunity to lead such a talented
and passionate Prothena team where we put patients and their
families at the center of everything we do,” said Dr. Swanson. “I
am very much looking forward to joining the executive leadership
team, working even more closely with the board and Gene, as we
continue to advance our potential best-in-class portfolio
addressing neurodegenerative and rare peripheral amyloid
diseases.”
Prior to his time at Eisai, Dr. Swanson was Senior Scientist and
US Head of Neurochemistry, Target Discovery and Assessment at
Lundbeck, Inc, where he led several discovery programs, and a
laboratory devoted to discovery and preclinical research in
psychiatric disease.
Dr. Swanson received his Ph.D. from the Medical University of
South Carolina in Physiology and Neuroscience, and his B.S. from
the University of Wisconsin–Madison in Zoology with neurobiology
emphasis.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics with the potential to change the
course of devastating neurodegenerative and rare peripheral amyloid
diseases. Fueled by its deep scientific expertise built over
decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and follow the
Company on Twitter @ProthenaCorp.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927197303/en/
Investors Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Dec 2023 to Dec 2024